These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21482412)

  • 1. SUMO and its role in human diseases.
    Sarge KD; Park-Sarge OK
    Int Rev Cell Mol Biol; 2011; 288():167-83. PubMed ID: 21482412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUMO on the road to neurodegeneration.
    Dorval V; Fraser PE
    Biochim Biophys Acta; 2007 Jun; 1773(6):694-706. PubMed ID: 17475350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sumoylation and human disease pathogenesis.
    Sarge KD; Park-Sarge OK
    Trends Biochem Sci; 2009 Apr; 34(4):200-5. PubMed ID: 19282183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal.
    Riley BE; Zoghbi HY; Orr HT
    J Biol Chem; 2005 Jun; 280(23):21942-8. PubMed ID: 15824120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on the cause-effect relationship between oxidative stress and toxic proteins in the pathogenesis of neurodegenerative diseases.
    Borza LR
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(1):19-27. PubMed ID: 24741770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNAi silencing in mouse models of neurodegenerative diseases.
    Farah MH
    Curr Drug Deliv; 2007 Apr; 4(2):161-7. PubMed ID: 17456035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SUMO and Parkinson's disease.
    Eckermann K
    Neuromolecular Med; 2013 Dec; 15(4):737-59. PubMed ID: 23979994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein aggregate characterization in models of neurodegenerative disease.
    Tebbenkamp AT; Borchelt DR
    Methods Mol Biol; 2009; 566():85-91. PubMed ID: 20058166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and alpha-synuclein.
    Dorval V; Fraser PE
    J Biol Chem; 2006 Apr; 281(15):9919-24. PubMed ID: 16464864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive and negative regulation of APP amyloidogenesis by sumoylation.
    Li Y; Wang H; Wang S; Quon D; Liu YW; Cordell B
    Proc Natl Acad Sci U S A; 2003 Jan; 100(1):259-64. PubMed ID: 12506199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conformationally altered proteins cause neurodegenerative diseases].
    Ingelsson M; Nilsson L; Basun H; Aquilonius SM; Lannfelt L
    Lakartidningen; 2005 Nov 21-27; 102(47):3542-3, 3545-6, 3549 passim. PubMed ID: 16408392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis.
    Dangoumau A; Veyrat-Durebex C; Blasco H; Praline J; Corcia P; Andres CR; Vourc'h P
    Int J Neurosci; 2013 Jun; 123(6):366-74. PubMed ID: 23289752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease.
    Neumann M; Müller V; Görner K; Kretzschmar HA; Haass C; Kahle PJ
    Acta Neuropathol; 2004 Jun; 107(6):489-96. PubMed ID: 14991385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUMOylation in Neurodegenerative Diseases.
    Princz A; Tavernarakis N
    Gerontology; 2020; 66(2):122-130. PubMed ID: 31505513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sumoylation is critical for DJ-1 to repress p53 transcriptional activity.
    Fan J; Ren H; Fei E; Jia N; Ying Z; Jiang P; Wu M; Wang G
    FEBS Lett; 2008 Apr; 582(7):1151-6. PubMed ID: 18339323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sumoylation: Implications for Neurodegenerative Diseases.
    Anderson DB; Zanella CA; Henley JM; Cimarosti H
    Adv Exp Med Biol; 2017; 963():261-281. PubMed ID: 28197918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sumoylation regulates lamin A function and is lost in lamin A mutants associated with familial cardiomyopathies.
    Zhang YQ; Sarge KD
    J Cell Biol; 2008 Jul; 182(1):35-9. PubMed ID: 18606848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUMOylation attenuates the aggregation propensity and cellular toxicity of the polyglutamine expanded ataxin-7.
    Janer A; Werner A; Takahashi-Fujigasaki J; Daret A; Fujigasaki H; Takada K; Duyckaerts C; Brice A; Dejean A; Sittler A
    Hum Mol Genet; 2010 Jan; 19(1):181-95. PubMed ID: 19843541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Battling Alzheimer's Disease: Targeting SUMOylation-Mediated Pathways.
    Martins WC; Tasca CI; Cimarosti H
    Neurochem Res; 2016 Mar; 41(3):568-78. PubMed ID: 26227998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
    Deger JM; Gerson JE; Kayed R
    Aging Cell; 2015 Oct; 14(5):715-24. PubMed ID: 26053162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.